Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Ipsen
  6. News
  7. Summary
    IPN   FR0010259150

IPSEN

(IPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ipsen : Irlab Enter License Deal on Potential Parkinson's Disease Treatment

07/16/2021 | 12:35am EDT


© MT Newswires 2021
All news about IPSEN
09/18Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progressio..
CI
09/17LAZARD : Reportedly Picked for Strategic Review of French Drugmaker Ipsen's Cons..
MT
08/16IPSEN : announces withdrawal of palovarotene NDA, confirming intention to re-sub..
AQ
08/13European stocks log best winning streak since 2006, fourth week of gains
RE
08/13European stocks log best winning streak since 2006, fourth week of gains
RE
08/13IPSEN : Drops US FDA Application for Ultra-Rare Genetic Disorder Drug
MT
08/13Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-Su..
CI
08/02Top Midday Gainers
MT
08/02EXICURE : Working With Ipsen to Develop Potential Therapeutics for Neurodegenera..
MT
08/02IPSEN : Exicure to Develop Treatment for Neurodegenerative Illnesses
MT
More news
Analyst Recommendations on IPSEN
More recommendations
Financials
Sales 2021 2 805 M 3 289 M 3 289 M
Net income 2021 588 M 689 M 689 M
Net Debt 2021 68,2 M 80,0 M 80,0 M
P/E ratio 2021 11,7x
Yield 2021 1,27%
Capitalization 6 770 M 7 947 M 7 939 M
EV / Sales 2021 2,44x
EV / Sales 2022 2,25x
Nbr of Employees 5 703
Free-Float 41,9%
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 82,32 €
Average target price 94,86 €
Spread / Average Target 15,2%
EPS Revisions
Managers and Directors
David G. Loew Chief Executive Officer & Director
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Marc M. P. de Garidel Non-Executive Chairman
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
IPSEN21.24%7 947
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604